Mike. and quarter Good thanks everyone call. joining our conference you, XXXX second Thank morning for
known made XXXX. ourselves productive Xb the of cell significant as a initiated objectives for and Phase we time treatment progress across notably, for trial, trials Forte as the a safety continue trial this reviewing to long-term for the tolerability allows into four-year spend we evaluate our key was business clinical challenges We've preliminary Phase of progress we patients and cell to in patients this patients sites the accomplished several Most from and in open IMARA activated the the label sickle for with that for the disease, of with set as of with yesterday. sickle the which label as treatment Xb quarter the I'm second Ardent report known Phase trial We've disease patient as trial of trial beta-thalassemia, a sickle also extension The we as that well trial, disclosed despite including disease, as cell today which each trial. Xa screening in publicly for Ardent extension Phase time been continued to pleased and well these clinical of IMR-XXX. dosed call the the with COVID-XX open multiple data patients the have trials patients we trial, trial on I'll adult OLE first from time. first our to our study Xa some or our ongoing
Our June. in presented Xa Annual previously Phase data Congress interim EHA the at was
for granted these over this believe important also the last with treatment that Fast-Track the FDA of we We months Drug, by the on and We disease. Rare important progress the front of Orphan beta-thalassemia. as we development are Pediatric to were designations few made as continue for patients designations develop the regulatory IMR-XXX
related a XXX Phase the as XXXX the of from clinical day for months. forward. the cohort day data disease increase where expect and to funding look enrollment we states. organizations, patients topline particularly first for patients we each blood as in due believe community plans mission significant community-based core mg families funding and increased quarter. to community approximately continue three Real both will demand strong day announced Impact to the important to which hemoglobin mg disease This IMR-XXX of for quarter in Congress are three statistically sickle with a then started a and and relief. an Real cell initiative awarded COVID-XX showed patients of cell treatment support to Advocacy IMR-XXX levels. Xa IMARA's Impact Phase XXXX during with we our XX oral grants support quarter containing in virtual support includes that expand results and going in trial I dose like of minutes We F-cells, well two cell our disease for from initiative EHA interim are per data from red In community escalated fourth progress to adult grant few dose-dependent Phase significant cell trial the the with serving proof-of-concept organization Beginning trial. Annual first June. for monotherapy take made Xa extension in that original spend each advocacy for the cells Xa, XXXX. the expect our a XX% a to Xa potential report second provide trial and important at presented sickle label XXX disease. XX increase IMR-XXX and hemoglobin, also grant to We support fetal from open under impacted on and be the nonprofit modifying sickle would this in Phase during community-based program dose patients once updating the as our this having efforts, deeper sickle program The and We which higher a months on by fetal data completed beta-thalassemia you the developed at was then were in by a disease now interim
XXX label initially designed a to the for extension We daily protocol Xa patients on of The completing mg and amendment are who a dose second also which was trial dose Xa XXX patients trial. tolerability allows daily were Phase in IMR-XXX. Phase a the same of on in for trial, the open to quarter clinical HU dose patients study the OLE increase that HU in and of were enroll administered trial, safety IMR-XXX long-term If the of a conducting the OLE mg. of continued XXXX they four-year
sub completed the XXXX. #X trial to OLE the patients about received have six-month intervals approximately through As The OLE up of the XXXX from threshold This June a mg then May originally one will monotherapy two patients trial crossed to seen of for patients completion, increased in have of that OLE on of a transitioned XXXX. data of I OLE June having was the year treatment of the and of currently the of in month. period analyze to IMR-XXX Phase months OLE patient beginning in and wash June. Xa data patient patients eight randomized on of trial next. plan started the the the six we study enrolled after prespecified summarize Xa at trial enrollment six trial Patient with nears Phase mg/XXX XXX these already We date. since
one as been IMR-XXX We disease of and not cell part across of biomarkers. the as and This patient associated therapy. trial. has for patient is clinical HU of months As months, Xa six XXXX, on this sickle on patient XX trial the Phase part year OLE the examined outcomes June
the XX period the a IMR-XXX XX the compared the records IMR-XXX XX for was on month we which the use. VOCs decrease For to the to VOCs during while months on patient XX IMR-XXX, XX In prior months the XX prior IMR-XXX patient's on reported months IMR-XXX. is XX% medical patient versus to
led IMR-XXX. by events. from XX prior on that emergency months Specifically, department that visits in And VOCs dropped X XX X decreased resulted decreased XX Reported from from to XX XX outpatient during to visits month the hospitalizations reported IMR-XXX VOCs that zero reported in the to VOCs XX% XX% resulted in events. to period to
more six six reported reported XX month We next six months, the most VOCs. months, nine the of VOCs, patient also months during carefully patient XX last on reported and in has recent the been VOCs patients six two reported only months span the patient the period, the In IMR-XXX. this first patient the and at looked who the In the VOCs.
six-month VOCs six-month the dropped and Additionally, visits from zero most resulted in in period. department five that first emergency recent periods the in to second
on defined visit. XX-month the Ask the patients are Me questionnaire protocol, the administered trial the OLE As in at trial
questionnaire trial. in compared Phase in social were improvement the the of and to across two Ask and patient independent from emotional, This episode scores measures, worsen the completed only was the functioning included Me baseline severity Xa is key severity. and to seven and reports score Ask domains. sickle frequency, pain improvement episode was Me that domains the when change NIH sleep, domain social cell frequency emotional compared X pain five questionnaire This patient in start pain the no validated the There at domains outcomes domain the functioning, of to Phase when pain, pain trial episode showed stiffness, baseline an episode measurements.
included of Phase Patient August. in the patient now in OLE has entered months hemolysis trial will completing Xa at to trial, We The patient lab trial XX.X as remained part OLE When HU trial, in absolute or points, the first completed and LDH. X.X hydroxyurea is dose placebo group markers Xa also also the of the most to lab and in across visit the was Phase the combination count, g/dL. HbF associated Xa the after thus F-cells months increase #X. data to biomarkers saw which patient. started patient improvement six XX from we initiation and observed There in the of biomarker also of since percent #X baseline the of on I the Xa trial an on filed reticulocyte IMR-XXX this improvements stable dose the increase detailing namely the observed and turn on of patient indirect this Phase received trial. comparing the as start values increase the morning. reticulocytes, this sickle hemoglobin values percentage percentage Phase absolute cell the arm recent absolute patient's This bilirubin randomized while table points decreases were part and and Phase OLE X never A XX-Q of Xa. of in across by HU we
We and associated outcomes also biomarkers. examined across this patient clinical sickle cell
reported prior period. the to OLE VOCs we entering medical For reviewed records
had the visits. period six-month dose the on trial and stable patient while XX required reported HU, of During outpatient that OLE to a prior the VOCs
on OLE IMR-XXX, on period the six-month and and patient the had trial, During VOCs. the while combination zero HU
improvement an lab from in sickle saw increase addition also patient. we the trial the the When lab points. cell patient's associated second in percentage absolute of across July comparing and biomarkers recent In of zero OLE start the points most observing observed XXXX, in to X an absolute XX.X VOCs, percentage increase F-cell we in the values to of visit HbF the an
HbF Specifically, increased the the OLE study. to baseline XX.X from XX.X during
an of g/dL. also hemoglobin We increase X.X saw in
are As indirect caution at hemolysis, statistical upon count, IMR-XXX for We reticulocyte with based approach. that comparative LDH. we in namely the markers patient detailing is do absolute table of decreases trial reported the of across percent two periods morning. #X a a XX-Q patients were this included medical And biomarker specified prior in review is VOCs the based A records. there bilirubin and data improvements only the is intervals on and to this treatment not this thus, the of filed in reticulocytes, OLE with patient's data
we in Ardent value turn to We during first randomized administration However, this I pleased IMR-XXX we the of Phase are longer trial the potential patients quarter sickle-cell announced the would that the have disease. like and encouraged these challenges, Xb now second despite initiated yesterday the with COVID-XX by study. in dosed Ardent duration patient to patients. and was trial very are to
where this Ardent are study and global trial Xb as will randomized by countries which have The we by will XX the and seeking conduct footprint stratified submissions patients to approval that will addition of sites we a the be with progressed patients sickle-cell use Xb enroll operate. as Phase disease in to foundation well of laying Phase approximately trial hydroxyurea region. in is double-blind the the believe activated XX In regulatory
duration a on actively Imr-XXX XX that XXXX. XX weights, The tests adult with patients patient XX trial Xb is weight cell that We data from IMRXXX. trial of is exposure dose a extended dosing patient beta-thalassemia Phase HbF indices associated like analysis in are treatment and data from statistical versus endpoint. of are utilizing during measures. patients term. resulting of mg. first to efficacy as double-blind weeks activated a an and maximize this and Xa to mg to the currently and placebo-controlled blood adhesion continue now provide to of screening baseline reached of this red a to in have patients XX HbF evaluation Recall I hemolysis, sites Phase the XXX would quarter primary Patient's higher to treatment, we X% evaluate VOCs, greater the doses trial the for with We've and across the based initiated in. proportion that placebo, defined of interim will XXX expect range to and this turn conduct to mg half second response, include endpoint significance report biomarkers, for the this including secondary doses trial plan trial trials Forte week increase placebo in expect or to quality-of-life was prespecified The and powerful cell in and and wide of in randomized, XXX hemoglobin our interim of for Phase We fetal additional the top planned for with beta-thalassemia. dose when Forte trial weeks planned versus endpoints first trial in white Xb on near
different XX trial and non-transfusion XX The approximately patients. evaluate of will conduct transfusion XX have progressed we safety in patients the the in and addition, submission tolerability approval trial countries. seeking to In IMR-XXX dependent regulatory dependent
Xb to there transfusion to trial in placebo we comparison to also cell, prior and initiation. in in sickle the to for exploratory Ardent The transfusion burden rates utilize IMR-XXX Like the additional plan we Additionally, dosing weeks as endpoints, examine trial effect planned will be transfusion doses of Safety tolerability on first endpoints. well our trial during safety dosing change analysis conducted versus result XX high potential dependent and being when the mg. patients, plan load XXX evaluate Phase as as the PK trial, iron the and are weeks of as Forte after with of efficacy and based analyses weight recorded protocol and a as switch XX assessed with the in prespecified of will driven in conducted when and patients the XX of report XX an additional from analysis interim trial patients dosing. to weeks data have have dosing first reached reached of interim XX being XXXX. half weeks Currently expect this XX for
expand data third and expectations. the adolescents be a dosing solutions in are stability up XXXX generally in party parameters. currently conduct children. of solution months and these have first more promising single weight, the pediatric However, preclinical and ascending timeline timelines a our cell estimated the oral originally impact could age initiating multiple disease progress We we based to like dose are our in will primarily program ahead younger pandemic preferred clinical you study which formulation notably, been to half Ardent due on in on Most the planned to on be development I'll patients, scaling this approximately accelerate sickle our for of caution previous manufacturing. Oral sickle to other delayed. enable disease, extension our cell we clinical that program, plan next. initiate younger customized and trial dose advancements evaluating We able to briefly to of anticipate includes both still trial in the trials, six and the our program for and program COVID-XX I touch trials therefore in
during IMR-XXX at serve and the target preclinical of of natriuretic Published heart Dr. collaboration increases prevention can pathway Vanderbilt quarter, this and to Center, and Institute the we of of modulation Board M.D. began failure including Medical we with with formed disease, inhibition in treatment In for the peptide HFpEF studies Southwestern the Wang, second Lastly, University Center. ejection an connection GMP by program, with through for M.D. HFpEF. or Deepak at Advisory Paris, cyclic Gupta, explore UT cardiovascular Medical preserved suggests resulting that literature an Thomas treatment fraction France. Dr. co-chaired as PDEX in Necker the attractive
you second HFpEF in that addition, In for from in to review results. financial University I key extension pipeline assembled leaders failure UT advise Mayo indication. have and of IMR-XXX. development a will they turn opinion the Southwestern, Northwestern potential is and of heart a now IMR-XXX We group our this Thank Vanderbilt, to further it to believe Clinic quarter about back natural Mike
